Healthcare telemedicine services company Banyan Medical Systems reported on Friday the launch of the philanthropic Telehealth Aid Programme for Hospitals (TAP4H) to enable isolation patients in hospitals to receive optimal care, while providing protection to the hospital staff.
Under the first phase of the TAP4H programme, the company pledges a USD1m investment to enable 100 isolation rooms across 20 hospitals in the US and plans to expand the programme into subsequent phases. Approved and participating hospitals will receive hardware, software, installation services and virtual care services at no cost for up to five rooms for three months.
The company added that the COVID-19 crisis demands minimal contact between patients and staff and hence introducing telemedicine to decrease the risk of infection and benefit the public.It will supplement local hospital with virtual professionals and technology to enable new use-cases. Many hospitals are currently dealing with an influx of patients and expect the surge to continue over the next several months.
Banyan also said that through its TAP4H programme, it is offering its platform to hospitals dealing with COVID-19 patients to enable isolation and treatment. These facilities can provide the best patient care through use of virtual medical staff, high-fidelity two-way video communication capabilities and healthcare-specific task coordination technology.
Using the company's telehealth services, MarinHealth, one of Banyan's partners located north of San Francisco, monitors COVID-19 patients remotely, from out-of-state medical call-centres and from virtual nursing stations within the walls of the hospital itself.
Sanofi agrees USD2.2bn acquisition of Dynavax to strengthen adult vaccine portfolio
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
NeuroSense Therapeutics completes safety evaluation of PrimeC in Alzheimer's Phase 2 study
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Ipsen licenses Simcere Zaiming antibody-drug conjugate for global development
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Ipsen closes Phase II FALKON trial after missing primary endpoint in FOP
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer